Here is my prediction for the longevity industry over the next ten years: the brands that will define it are not the ones with the most advanced technology.
They are the ones that understand that a human being is not a collection of optimisable biological systems.
This needs explaining, because the technology matters. I spend significant time at the frontier of longevity science — the peptide protocols, the hyperbaric chambers, the IV panels, the methylation interventions — and the serious work in this space is genuinely important. Some of it is remarkable. The biology is real. The interventions work.
But I am also watching a pattern emerge in how clients experience even the best-resourced longevity programmes. They come in. They are comprehensively assessed. They receive excellent science. They are told what to eat, how to train, what to supplement, what to stop doing. And then — often, not always — they leave and do not implement the programme. Or they implement it for three months, and then life and stress and human nature reassert themselves.
The limitation is not the science. It is the model.
The longevity industry, in its current dominant form, treats the person as a biological machine requiring calibration. What are the inputs that produce optimal outputs? This is a useful question. It is not a sufficient one.
The question it is not yet asking consistently is: what does this person actually need to feel that being alive is worth extending? What is the relationship between their sense of meaning, their quality of connection, their capacity for genuine pleasure, and the biological metrics we are trying to move? What does the person sitting across from you actually believe about whether they deserve to be well?
These are not soft questions. The research connecting psychological state to biological outcomes — stress hormones and inflammation, loneliness and immune function, purpose and mortality risk — is as rigorous as anything else in this field. It just requires a different kind of infrastructure to address. And building that infrastructure is harder than buying a better machine.
The brands that will win the next decade are the ones building that infrastructure now. Not instead of the clinical science — alongside it. Programmes that integrate biomarker data with a genuine understanding of the whole person. Environments designed for the felt experience of being alive, not just the measured one. Teams that include both physicians and practitioners whose expertise is in the dimensions of human experience the blood panel cannot capture.
The longevity industry has borrowed its model predominantly from medicine: diagnose, prescribe, treat. This is appropriate for clinical settings and for the more acute interventions. But for the long-term behavioural and lifestyle work that actually determines healthspan, a different model is needed — one that starts with the question of what the person actually needs to show up for their own life differently.
After thirty years working at the intersection of wellness, science, and human experience, I believe the field that gets closest to the whole person will be the one that endures.
Precision medicine is not the destination. It is the beginning of a more interesting conversation.
The brands that understand this earliest will not necessarily be the largest or the most technologically equipped. They will be the most trusted — because trust, as it turns out, is a longevity metric too.